CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED)

Clinical trials for CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED) explained in plain language.

Never miss a new study

Get alerted when new CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED) trials appear

Sign up with your email to follow new studies for CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for kids with Ultra-Rare, aggressive cancers

Disease control Ongoing

This study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control rare, aggressive cancers in children and young adults. The trial is for patients whose cancers have returned or haven't responded to standard treatments. Researchers…

Matched conditions: CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED)

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED)

Get alerted when new CHORDOMA (POORLY DIFFERENTIATED OR DE-DIFFERENTIATED) trials appear

New hope for kids with Ultra-Rare, aggressive cancers